WRSs2 Shigella Vaccine Shows 89% Efficacy in Phase 2 Trial

A Phase 2 controlled human infection trial for the WRSs2 live-attenuated oral Shigella sonnei vaccine has yielded an 89% protective efficacy rate after two doses. Conducted by researchers at Cincinnati Children's Hospital Medical Center, the study involved 73 participants who completed the challenge phase, with no serious adverse events reported. These findings, published in The Lancet Infectious Diseases on September 13, 2026, represent the highest efficacy recorded for any Shigella vaccine candidate so far.

This development marks a significant step in the century-long search for a way to prevent shigellosis, a severe diarrheal disease caused by the pathogen Shigella sonnei. While researchers have worked for decades to produce a licensed vaccine, previous candidates often failed to reach the necessary level of efficacy. The results from the WRSs2 trial suggest a shift in that history, offering evidence of progress against a difficult target. The research team noted that continued investment remains vital to meeting public health needs, especially among populations most at risk.

The trial relied on rigorous testing protocols and close collaboration between researchers and healthcare professionals. By prioritizing participant safety and ethical standards, the study design allowed for a thorough assessment of how well the vaccine works. Completing the challenge phase without serious adverse events reflects the precision of the trial’s execution. As the team analyzes the resulting data, these findings will guide the planning for larger trials and the eventual deployment of the vaccine to vulnerable groups.

An effective Shigella vaccine carries broad implications for social and economic stability. Currently, these infections place a heavy burden on healthcare systems, particularly in areas where clean water and sanitation are scarce. A successful vaccine could allow public health programs to lower the incidence of shigellosis significantly, improving the quality of life for millions of people. Beyond the immediate health benefits, a licensed vaccine would help ease the financial pressure on medical infrastructure and strengthen community resilience against infectious outbreaks.

The success of this Phase 2 trial paves the way for larger studies to evaluate the vaccine's performance in broader, high-risk populations. The research team sees a clear path toward the WRSs2 vaccine becoming a licensed product, a move that would be a major milestone in the global effort to manage diarrheal diseases. This ongoing work highlights the role of steady innovation and partnership in tackling global health challenges, moving closer to a tool that can save lives and improve health outcomes on a wide scale.